Clinical trial ADRIATIC
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (D933QC00001 - ADRIATIC)
| Cancers | |
|---|---|
| Organ | Lung |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | AstraZeneca |
| EudraCT Identifier | 2018-000867-10 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03703297 |
| Inclusion criteria | 4 lines chemotherapy and radiation |
| Last update |